Olaparib-induced interstitial lung disease: A case series analysis

Abstract

Olaparib-induced interstitial lung disease (OILD) is a rare but potentially serious adverse event, and its imaging characteristics and clinical course remain unclear. Ishimoto et al. previously reported three cases of OILD, but further characterisation is needed. We present three additional cases, all presenting with fever and bilateral ground-glass opacities (GGO) and fine reticulonodular opacities on computed tomography (CT). Bronchoalveolar lavage fluid (BALF) analysis showed marked lymphocytosis (>75 %). Prednisolone (0.5–1 mg/kg/day) was effective without fibrosis. BALF lymphocytosis may aid in the diagnosis of OILD. OILD should be considered in febrile patients receiving olaparib.